All News

IL17

Expanding the IL-17 Therapeutic Landscape

Adela Castro, MD

IL-17 inhibitors are an effective therapeutic for a broad spectrum of inflammatory and autoimmune diseases and its blockade has revolutionized management of diseases such as psoriasis, psoriatic arthritis and SpA. Is there a need for more medications within the same therapeutic class?

Read Article
vaccination.jpg

Safety of Recombinant Zoster Vaccine in Rheumatic Patients

EurekAlert!

New work presented at the 2025 annual EULAR congress in Barcelona focuses on the recombinant zoster vaccine (RZV), which contains recombinant glycoprotein E – the major target of CD4+T-cells.

Read Article
uveitis eye iritis

Putting IL17i into ‘focus’ for SpA-associated uveitis

Janet Pope, MD, MPH, FRCPC

The longest studied drug for uveitis in SpA has been monocolonal TNFi Abs. Reductions of acute anterior uveitis have been found with etanercept but less impressively than adalimumab, infliximab, and in my opinion less than golimumab and certolizumab pegol.

Other data have emerged for JAKi and IL17i, with respect to acute anterior uveitis.

Read Article
diversity together global leadership

Difficult-to-Manage AxSpA: Global Prevalence and Associated Factors

Nelly Ziade

The concept of Difficult-to-Manage (D2M) axial spondyloarthritis (axSpA) is a recent development, with the first expert consensus definition published by the Assessment of SpondyloArthritis International Society (ASAS) earlier this year. This unified definition has stimulated a wave of new research globally, with multiple studies analysing D2M axSpA in diverse clinical cohorts.

Read Article
#D2M_axSpA_saga 🇬🇷 Prevalence of D2M axSpA in 395 patients: 10.1% Associated factors: 🔹️High disease activity at diagnosis 🔹️Comorbidities (high BMI, smoking, depression) 🔹️Unemployment Kougkas et al. POS#0121 #EULAR2025 @rheumnow https://t.co/vcPcTATTx5

Links:

Nelly ZIADE 🍀 Nellziade ( View Tweet)
🚨Diagnostic delays are real in axSpA: -Can lead to more extra-msk manfieststions (EMMs) in PsA and axSpA. -Increases disease burden and productivity losses. -EMMs can present before articular sx -Uveitis and IBD associated with longer dx delays. -Diagnosis has improved since https://t.co/rWMwG7Ewwe

Links:

Adela Castro AdelaCastro222 ( View Tweet)
📊 SIJ findings in PsA (n=581): 🧠 31% = MRI-confirmed axSpA 🦴 Only 29% met r-mNY criteria MRI-axPsA group: younger, more male, HLA-B27+ Clinical + radiographic definitely underperform vs MRI #POS0297 @RheumNow #EULAR2025

Jiha Lee JihaRheum ( View Tweet)

High dose NSAIDs and incidence of HTN in axSpA? In pts with early axSpA(age at baseline 33.2 years) data from DESIR cohort showed that after adjusting for confounders,high dose NSAID use was not associated with incident hypertension (HR 1.01, 95% CI 0.98-1.02). Interesting to

Adela Castro AdelaCastro222 ( View Tweet)

What is new in SpA? ‼️nomenclature change: 🚫AS≠ Ankylosing spondylitis ✅AS= Axial spondyloarthritis -Helena Marzo-Ortega at #EULAR2025 @RheumNow

Adela Castro AdelaCastro222 ( View Tweet)

Delay hurts. Dx delay in axial SpA costs UK £3.1 billion annually. Avg time to dx = 8.5 yrs Avg dx cost = £187k/person Fixing delay could save £167k/person. Early Dx isn’t just better care—it’s economic policy. #EULAR2025 @RheumNow #AxialSpA #RMD https://t.co/eYEQ2rp94m

Links:

Jiha Lee JihaRheum ( View Tweet)
Diagnostic delay in #SpA 🔹️Data from the @Official_ASAS Study 🔹️4339 patients 🔹️Delay was 6.6 years 🔹️Longer in axSpA and IBD-SpA, shorter in PsA and pSpA 🔹️Associated with type of initial symptoms (shorter in peripheral) POS0909 #EULAR2025 @rheumnow https://t.co/3BMYFxbKiq

Links:

Nelly ZIADE 🍀 Nellziade ( View Tweet)
LDCT to assess disease progression in early axSpA: -Data from SPACE cohort 67 pts (>50% male,>80% hLAB27+) - LDCT at baseline and 2 years apart. -Overall 22% pt with net disease progression. -Spine progression most frequent on thoracic spine. -Good reliability in assessing https://t.co/M2jkDusD41

Links:

Adela Castro AdelaCastro222 ( View Tweet)
In #axSpA post #TNFi-IR What to use next? 👇 #ATTRA registry 90% #SpA on #bDMARDs are captured Comparison of TNFi to ▶️ 2nd TNFi vs #IL17i ▶️No diff in #retention ✅better #BASDAI and other outcomes w TNFi! ❎less safety 🤔 #EULAR2025 @RheumNow @eular_org Abst#POS0116 https://t.co/7mqFfD4Amf

Links:

Janet Pope Janetbirdope ( View Tweet)
Data from Dutch registry SpA-Net explored prevalence using new definitions for D2M axSpA. -Smoking and psoriasis were characteristics associated with D2M disease. -In the three variations explored, the lowest prevalence was observed in the variation based purely on objective https://t.co/h3f4ORQl0F

Links:

Adela Castro AdelaCastro222 ( View Tweet)
Insights from the Gut-Joint Axis in axSpA: Findings from the DESIR cohort -Baseline biomarkers of bacterial translocation: PLTP (phospholipid transfer protein) and LPS evaluated. -In early axSpA baseline PLTP activity was associated with sacroiliac radiographic progression at 5

Adela Castro AdelaCastro222 ( View Tweet)

Precision immunotherapy in axial spondyloarthritis: TRBV9xCD3 bispecific antibodies selectively depleted autoreactive TRBV9+ T cells from HLA-B27+ AS patient samples while sparing over 95 percent of the T cell repertoire. TRBV9xCD3 bispecific antibodies selectively depleted https://t.co/8UXqEaDYnS

Links:

Antoni Chan MD (Prof) synovialjoints ( View Tweet)
Data from a German cohort evaluated the frequency of D2M-axSpA using the new D2M definition and showed: > Female pts > Peripheral SpA symptoms < HLAB27 positive < Education level < Objective signs: MRI-inflammation in the spine or elevated CRP levels. also PROs were worse in

Adela Castro AdelaCastro222 ( View Tweet)

GI symptoms in axSpA -Cohort of 370 pts with axSpAfrom New Zealand -Elevated fecal calprotectin ➡️ positive correlation with GI symptoms and high disease activity -Bowel symptoms associated with reduced quality of life. -Use of TNFi improved bowel symptoms over time. https://t.co/wA37G3HWyi

Links:

Adela Castro AdelaCastro222 ( View Tweet)
A PT-led vocational intervention for RA/axSpA with reduced work ability was likely cost-effective: ↓€4,324 in societal costs & +0.05 QALYs over 12m vs usual care (95% probability at €20k/QALY). Results suggest cost-effective compared to usual care. @RheumNow #EULAR2025 #OP0007

Mrinalini Dey DrMiniDey ( View Tweet)

Xeligekimab in AS: -IL-17A blocker -Phase 3 study on Chinese pts showed sustained efficacy until week 48. -Significant improvement on DAI measures as well. -Fully humanized IgG4 mab may last longer in system and possible less ADAs. Abstract #OP0102 #EULAR2025 @RheumNow https://t.co/vyNHZ9ssFt

Links:

Adela Castro AdelaCastro222 ( View Tweet)
How well do you know this week's rheumatology news?
Take the rheumIQ quiz
Take the RheumIQ Quiz

×